via Institute of Cancer Research
Scientists led by an NIHR Research Professor have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours.
Their cutting-edge technique uses artificial intelligence to analyse large-scale protein data from tumour samples, and is able to predict patients’ response to drugs more accurately than is currently possible.
Genetic analysis of tumours can reveal mutations that are fuelling cancers growth, some of which can be targeted with treatment – but genomics alone does not provide sufficiently accurate predictions to select drug combinations.
Scientists at The Institute of Cancer Research (ICR), London, tested the new technique on individual cancer cells in the lab and tumour cells freshly isolated from lung fluid in people with non-small cell lung cancer.
Their study is published in the journal Molecular Cancer Therapeutics today (Monday), and was funded by NIHR, Wellcome, Cancer Research UK and ICR.
Scientists carried out ‘proteomic’ analyses – examining changes in 52 important proteins and how they interact with each other in response to drug treatments. Researchers then trained machine learning algorithms to define the key protein changes that predict drug responses.
First, the researchers used the algorithm to predict how sensitive cells were to individual cancer drugs. They found that the technique could predict individual drug responses more accurately than genetic features, such as mutations in key genes EGFR, KRAS and PIK3CA – three genetic markers currently used in the clinic to predict drug responses in lung cancer.
Researchers then used the same approach to predict sensitivity to drug combinations – using 21 different two-drug combinations in lung cancer cells with different gene faults, such as mutations in EGFR and KRAS.
Of 252 total drug combinations, 128 showed some level of synergy, meaning their combined effect exceeded the effect of each individual drug added together.
Of these, the AI test correctly identified the top five ranked combinations 57 per cent of the time and the top 10 ranked combinations 83 per cent of the time.
The test successfully identified combinations that have previously been shown to have promise – for example, combinations of trametinib and capivasertib, or gefitinib and everolimus, in non-small cell lung cancer cell lines with EGFR mutations.
Researchers were also able to identify possible new combinations such as vemurafenib and capivasertib, which the test found could potentially be effective for non-small cell lung cancer cell lines with no mutations in EGFR or KRAS.
This is therefore the first prototype test that can offer personalised predictions of which drug combinations are likely to work in different individuals. Researchers at the ICR believe the new technology could be crucial in overcoming cancer evolution and treatment resistance by allowing doctors to analyse how drugs work in combination.
Study leader NIHR Research Professor Udai Banerji, Professor of Molecular Cancer Pharmacology at ICR, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:
“Our test provides proof of concept for using AI to analyse changes in the way information flows within cancer cells and makes predictions about how tumours are likely to respond to combinations of drugs.
“With a rapid turnaround time of less than two days, the test has the potential to guide doctors in their judgements on which treatments are most likely to benefit individual cancer patients. It is an important step to move forward from our current focus on using genetic mutations to predict response.
“Our findings show that our innovative approach is feasible, and makes more accurate predictions than genetic analysis for patients with non-small cell lung cancer. Before this test can enter the clinic and guide personalised treatment, we will need to further validate our findings – for example, by carrying out a study where we run the test in patients already getting a treatment to check if the predictions are correct.”
Original Article: AI test could predict effective cancer drug combinations in less than two days
More from: Institute of Cancer Research
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Predicting cancer drug combinations
- US FDA approves ImmunityBio's bladder cancer therapy
The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an end to the company's efforts to bring its therapy to the market.
- AI test could predict effective cancer drug combinations in less than two days
Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours. Their cutting-edge technique uses artificial ...
- NIH Researchers Develop AI Tool with Potential to More Precisely Match Cancer Drugs to Patients
Proof-of-concept study analyzed a newer technology known as single-cell RNA sequencing.
- Immunotherapy and Cancer Vaccine Combination for Hepatocellular Cancer
A recent phase 1/2 study (NCT04251117) evaluated one such combination approach, including PD-1 blockade and a personalized therapeutic cancer vaccine (PTCV). The researchers recently published their ...
- Immunotherapy During Pregnancy Just as Safe as Other Cancer Drugs
However, of note, preterm birth was significantly over-reported among women treated with a combination of anti-PD-1 and anti-CTLA-4 therapies compared with other anticancer drugs (80% vs 23% ...
Go deeper with Google Headlines on:
Predicting cancer drug combinations
[google_news title=”” keyword=”predicting cancer drug combinations” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Personalised drug predictions
- Personalized risk prediction tool helps prioritize high-risk infants for RSV prevention
A new tool to identify infants most at risk for severe respiratory syncytial virus (RSV) illness could aid pediatricians in prioritizing children under 1 to receive a preventive medication before RSV ...
- U.S. health care evolving to become more personalized, consumer-focused, research finds
Trends that could impact the market’s future, include the potential for future pandemics, emerging advancements in healthcare technologies and an aging population.
- First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution
With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting.
- AI Tool Forecasts Cancer Therapy Outcomes Using Single-Cell Insights
PERCEPTION, an AI-based approach predicts cancer treatment responses at single-cell resolution. The method, validated in clinical trials, analyzes tumor dynamics and drug resistance, aiming to refine ...
- AI tool predicts responses to cancer therapy using information from each cell of the tumor
With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting. Most of the focus has been on developing genetic ...
Go deeper with Google Headlines on:
Personalised drug predictions
[google_news title=”” keyword=”personalised drug predictions” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]